Company Overview and News

Brookfield Real Estate Services' (BREUF) CEO Phil Soper on Q4 2017 Results - Earnings Call Transcript

2018-03-07 seekingalpha
Brookfield Real Estate Services Inc. (OTCPK:BREUF) Q4 2017 Earnings Conference Call March 7, 2018 10:00 AM ET
Upvote Downvote

The Whole Is Greater Than Its Parts

2018-03-06 seekingalpha
They agree on many things, including the importance of being macro-oriented and using options strategies as a hedge against risk and to enhance returns.
Upvote Downvote

TheBaron Investing: Marijuana Collapses

2018-02-05 seekingalpha
The market has decided to cool on marijuana companies, which is appropriate but frustrating to see an undervalued company decline.
Upvote Downvote

Dividend Sensei Positions For 2018: Something Is Always On Sale

2018-01-03 seekingalpha
My goal is to generate maximum safe yield, with fast dividend growth, and buy stocks at their most undervalued.
Upvote Downvote

TheBaron Investing: Happy New Year Update

2017-12-29 seekingalpha
Some major sales and purchases have changed the portfolio weightings, along with one major addition to my current holdings.
Upvote Downvote

Our Most Undervalued High Yield Real Estate Play Is Not A REIT

2017-12-13 seekingalpha
The dividend is extremely well covered and will be covered even after premium  franchise fees go away.
Upvote Downvote

Brookfield Real Estate Services: Our Most Undervalued High Yield Real Estate Play Is Not A REIT

2017-12-13 seekingalpha
The dividend is extremely well covered and will be covered even after premium  franchise fees go away.
Upvote Downvote

BRIEF-Brookfield Real Estate Services Announces Acquisition Of Franchise Agreements

2017-12-08 reuters
Upvote Downvote

This 8% Dividend Yielder With A 60% Payout Ratio Just Hiked

2017-08-12 seekingalpha
The stock is still a strong buy in spite of fears of a Toronto housing market crash.
Upvote Downvote

Brookfield Real Estate Services' (BREUF) CEO Philip Soper on Q2 2017 Results - Earnings Call Transcript

2017-08-11 seekingalpha
Brookfield Real Estate Services Inc. (OTCPK:BREUF) Q2 2017 Earnings Conference Call August 10, 2017 10:00 AM ET
Upvote Downvote

Brookfield Real Estate Services: An Undervalued Small Cap With A 138% Covered 8% Yield

2017-05-24 seekingalpha
BREUF collects royalties from real estate agents for using its brands Royal LePage, Via Capitale Real Estate Network & Johnston & Daniel.
Upvote Downvote

Ontario Set to Unveil Its Plan to Cool Toronto Housing - Bloomberg

2017-04-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

Brookfield Real Estate Services' (BREUF) CEO Philip Soper on Q4 2016 Results - Earnings Call Transcript

2017-03-09 seekingalpha
Brookfield Real Estate Services, Inc. (OTCPK:BREUF) Q4 2016 Earnings Conference Call March 9, 2017 10:00 AM ET
Upvote Downvote

U.S. Interest in Canadian Real Estate Surges Following U.S. Presidential Election

2017-01-20 prnewswire
Forty per cent of real estate advisors believe that American inquiries will continue to climb after Donald Trump assumes power
Upvote Downvote

Vancouver’s housing market may be returning from ‘insanity’

2016-12-30 thestar
Vancouver’s long-awaited housing correction may be around the corner: prices are headed for a double-digit decline in 2017 as buyers drop out of the market, according to the head of Canada’s largest real estate services company.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...